ArriVent BioPharma entered to exclusive license agreement with Lepu Biopharma for MRG007, an ADC targeting GI cancers 

ArriVent gains exclusive rights to develop and commercialize MRG007 outside Greater China (mainland China, Hong Kong, Macau, Taiwan) 

Strategically it enhances ArriVent’s ADC portfolio, focusing on cancers with high unmet needs as its next plan is to advance MRG007 to clinical development 

ArriVent sees MRG007’s potential and aims to expand its ADC portfolio and with Lepu; is eager to bring the therapy globally 

MRG007 demonstrates strong antitumor activity and a favorable therapeutic index in preclinical GI cancer models 

IND Submission is planned for 1H 2025 and they are focusing on CRC, pancreatic, and other GI cancers 

Lepu to receives $47M upfront, up to $1.16B in milestones and royalties 

No impact on ArriVent’s expected cash runway through 2026 despite the upfront and milestone payments